Evoke Pharma Inc (EVOK) Actualités

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti...

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 3 - Initial statement of beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]